Head and Neck Cancer Market Size & Share to Surpass USD 2.9 billion by 2031 | Transparency Market Research, Inc.
January 02, 2024 09:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - Head and neck cancer market was valued at US$ 1.6 billion in 2022. A CAGR of 6.8% is...
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong...
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023 12:01 ET
|
HOOKIPA Pharma Inc.
HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were...
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
October 22, 2023 06:01 ET
|
HOOKIPA Pharma Inc.
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...
Global Radiation Oncology Market Expected to Reach $21.14 Billion by 2030: Technological Advancements and Global Cancer Burden Drive Growth
July 25, 2023 07:08 ET
|
Research and Markets
Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Radiation Oncology Market Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By...
AI in Oncology Market Report 2023-2033: Accelerated Drug Discovery and Targeted Therapies Driving Growth
July 21, 2023 06:13 ET
|
Research and Markets
Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global revenue for...
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer
June 14, 2023 08:00 ET
|
PDS Biotechnology Corporation
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed...
Global Radiation Oncology Market Report 2023: Demand for Advanced Cancer Treatment Options Fuels Growth
June 06, 2023 05:28 ET
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global radiation...
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
May 25, 2023 17:00 ET
|
PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
May 15, 2023 07:30 ET
|
PDS Biotechnology Corporation
Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE...